<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620213</url>
  </required_header>
  <id_info>
    <org_study_id>OPI-NYXRM-301 (MIRA-2)</org_study_id>
    <nct_id>NCT04620213</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis</brief_title>
  <official_title>Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocuphire Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocuphire Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
        -  To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced&#xD;
           mydriasis across multiple mydriatic agents with an emphasis on phenylephrine&#xD;
&#xD;
        -  To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after&#xD;
           worsening (with cycloplegic agents tropicamide and Paremyd)&#xD;
&#xD;
        -  To evaluate the safety of Nyxol&#xD;
&#xD;
        -  To evaluate any additional benefits of the reversal of pharmacologically-induced&#xD;
           mydriasis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, parallel arm, double-masked, placebo-controlled Phase 3 study in at least 168&#xD;
      randomized subjects (160 completed), evaluating the safety and efficacy of Nyxol in subjects&#xD;
      with pharmacologically-induced mydriasis.&#xD;
&#xD;
      Following the successful completion of screening, each subject will be stratified by eye&#xD;
      color and then simultaneously be randomized to mydriatic agent (unmasked) and treatment&#xD;
      (masked).&#xD;
&#xD;
      Treatment randomization will be 1:1, Nyxol or placebo (vehicle).&#xD;
&#xD;
      Stratification by iris color will be 1:1, light or dark irides.&#xD;
&#xD;
      The mydriatic agent randomization will be 3:1:1 (2.5% phenylephrine, 1% tropicamide, and&#xD;
      Paremyd). That is, approximately 60% of the randomized subjects will receive one drop of 2.5%&#xD;
      phenylephrine 1 hour before treatment (96 completed subjects), approximately 20% will receive&#xD;
      one drop of 1% tropicamide 1 hour before treatment (32 completed subjects), and approximately&#xD;
      20% will receive Paremyd 1 hour before treatment (32 completed subjects).&#xD;
&#xD;
      At the treatment visit, subjects who have been randomized and stratified by iris color (1:1&#xD;
      [light/dark]) will receive one of three approved mydriatic agents approximately 1 hour prior&#xD;
      to receiving study treatment. Measurements will be measured before (-1 hour /baseline) and 60&#xD;
      minutes after (maximum/0 minutes) the mydriatic agent instillation in each eye (i.e. right&#xD;
      before the study treatment is administered), and at 30 minutes, 60 minutes, 90 minutes, 2&#xD;
      hours, 3 hours, 4 hours, and 6 hours after treatment dosing. Measurements will include pupil&#xD;
      diameter (PD), distance and near visual acuity (VA), accommodation, and redness in each eye.&#xD;
&#xD;
      At the Follow-Up Visit, which is 1 day after Visit 1, measurements will again be recorded 24&#xD;
      hours after treatment dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Actual">March 15, 2021</completion_date>
  <primary_completion_date type="Actual">December 23, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Subjects' Study Eyes with Pupil Diameter Returning to Baseline</measure>
    <time_frame>90 minutes</time_frame>
    <description>Percentage of subjects' study eyes returning to less than or equal to 0.2 mm from baseline pupil diameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Pupil Diameter Returning to Baseline</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Percentage of subjects returning to less than or equal to 0.2 mm from baseline pupil diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupil Diameter (Change from Max)</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Change (mm) from maximum pharmacologically-induced mydriatic pupil diameter (0 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Unchanged Accommodation from Baseline</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>Percentage of subjects with unchanged accommodation from baseline (-1 hour)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Mydriasis</condition>
  <condition>Dilation</condition>
  <arm_group>
    <arm_group_label>Phentolamine Ophthalmic Solution 0.75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phentolamine Ophthalmic Solution Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine Ophthalmic Solution 0.75%</intervention_name>
    <description>0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist</description>
    <arm_group_label>Phentolamine Ophthalmic Solution 0.75%</arm_group_label>
    <other_name>Nyxol</other_name>
    <other_name>Nyxol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phentolamine Ophthalmic Solution Vehicle (Placebo)</intervention_name>
    <description>Topical sterile ophthalmic solution</description>
    <arm_group_label>Phentolamine Ophthalmic Solution Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females ≥ 12 years of age&#xD;
&#xD;
          2. Otherwise healthy and well controlled subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ophthalmic (in either eye):&#xD;
&#xD;
          1. Clinically significant ocular disease as deemed by the Investigator that might&#xD;
             interfere with the study&#xD;
&#xD;
          2. Unwilling or unable to discontinue use of contact lenses at screening until study&#xD;
             completion&#xD;
&#xD;
          3. Unwilling or unable to suspend use of topical medication at screening until study&#xD;
             completion&#xD;
&#xD;
          4. Ocular trauma, ocular surgery or non-refractive laser treatment within the 6 months&#xD;
             prior to screening&#xD;
&#xD;
          5. Use of any topical prescription or over-the-counter (OTC) ophthalmic medications of&#xD;
             any kind within 7 days of screening&#xD;
&#xD;
          6. Recent or current evidence of ocular infection or inflammation in either eye&#xD;
&#xD;
          7. History of diabetic retinopathy or diabetic macular edema&#xD;
&#xD;
          8. Closed or very narrow angles that in the Investigator's opinion are potentially&#xD;
             occludable if the subject's pupil is dilated&#xD;
&#xD;
          9. History of any traumatic (surgical or nonsurgical) or non-traumatic condition&#xD;
             affecting the pupil or iris&#xD;
&#xD;
         10. Known allergy or contraindication to any component of the mydriatic agents or the&#xD;
             vehicle formulation&#xD;
&#xD;
         11. History of cauterization of the punctum or punctal plug (silicone or collagen)&#xD;
             insertion or removal&#xD;
&#xD;
        Systemic:&#xD;
&#xD;
          1. Known hypersensitivity or contraindication to α- and/or β adrenoceptor antagonists.&#xD;
&#xD;
          2. Clinically significant systemic disease that might interfere with the study&#xD;
&#xD;
          3. Initiation of treatment with or any changes to the current dosage, drug or regimen of&#xD;
             any systemic adrenergic or cholinergic drugs within 7 days prior to screening, or&#xD;
             during the study&#xD;
&#xD;
          4. Participation in any investigational study within 30 days prior to screening&#xD;
&#xD;
          5. Females of childbearing potential who are pregnant, nursing, planning a pregnancy, or&#xD;
             not using a medically acceptable form of birth control&#xD;
&#xD;
          6. Resting HR outside the normal range (50-110 beats per minute)&#xD;
&#xD;
          7. Hypertension with resting diastolic BP &gt; 105 mmHg or systolic BP &gt; 160 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Site 11</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 10</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 9</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <zip>32779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 6</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 2</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 7</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 3</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 5</name>
      <address>
        <city>Athens</city>
        <state>Ohio</state>
        <zip>45701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 12</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 1</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 8</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02888</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 4</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nyxol</keyword>
  <keyword>Pharmacologically Induced Mydriasis</keyword>
  <keyword>Dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mydriasis</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

